sotalol has been researched along with Ventricular Dysfunction, Left in 15 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily." | 9.08 | Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. ( Camm, AJ; deRuyter, H; Friedman, PL; MacNeil, DJ; Pauls, JF; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1996) |
| "This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction." | 7.75 | d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing. ( Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009) |
| "Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily." | 5.08 | Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. ( Camm, AJ; deRuyter, H; Friedman, PL; MacNeil, DJ; Pauls, JF; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1996) |
| "The Survival With ORal D-sotalol (SWORD) trial tested the hypothesis that the prophylactic administration of oral d-sotalol would reduce total mortality in patients surviving myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) of < or = 40%." | 5.08 | Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? ( Camm, AJ; Cooper, W; Friedman, PL; MacNeil, DJ; Moulton, KM; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1998) |
| "A case is described of cardiogenic shock that occurred following use of sotalol in a patient with severe left ventricular dysfunction." | 3.81 | Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy. ( Bergin, P; Kaye, DM; Mariani, JA; McGiffin, DC; Saxena, P; Stokes, MB, 2015) |
| "This study evaluated antiarrhythmic effects of d,l-sotalol in a canine atrial fibrillation (AF) model with left ventricular dysfunction." | 3.75 | d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing. ( Fujiki, A; Hashimoto, N; Inoue, H; Mizumaki, K; Nakatani, Y; Sakabe, M; Sakamoto, T, 2009) |
| "Cardiac mortality and sudden cardiac death rates also were higher in group 3 patients." | 1.32 | Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. ( de Paola, AA; Fenelon, G; Friedman, PA; Leite, LR; Silva, GG; Simoes, A, 2003) |
| "Average follow up at first AF recurrence was 18." | 1.31 | Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. ( Bacchi Reggiani, L; Bartolotti, M; Biffi, M; Boriani, G; Branzi, A; Zannoli, R, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (53.33) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stokes, MB | 1 |
| Saxena, P | 1 |
| Mariani, JA | 1 |
| Kaye, DM | 1 |
| Bergin, P | 1 |
| McGiffin, DC | 1 |
| Sakamoto, T | 1 |
| Fujiki, A | 1 |
| Nakatani, Y | 1 |
| Sakabe, M | 1 |
| Mizumaki, K | 1 |
| Hashimoto, N | 1 |
| Inoue, H | 1 |
| Kanorskiĭ, SG | 1 |
| Kanorskaia, IuS | 1 |
| Leite, LR | 1 |
| Fenelon, G | 1 |
| Simoes, A | 1 |
| Silva, GG | 1 |
| Friedman, PA | 1 |
| de Paola, AA | 1 |
| Exner, DV | 1 |
| Klein, GJ | 1 |
| Waldo, AL | 3 |
| Camm, AJ | 3 |
| deRuyter, H | 2 |
| Freidman, PL | 1 |
| MacNeil, DJ | 3 |
| Pitt, B | 3 |
| Pratt, CM | 3 |
| Rodda, BE | 1 |
| Schwartz, PJ | 3 |
| Friedman, PL | 2 |
| Pauls, JF | 1 |
| Veltri, EP | 2 |
| Ghali, JK | 1 |
| Tan, LB | 1 |
| Gottlieb, SS | 1 |
| Singh, S | 1 |
| Munger, M | 1 |
| Eichhorn, EJ | 1 |
| Ilgenfritz, J | 1 |
| Hanyok, J | 1 |
| Cooper, W | 1 |
| Moulton, KM | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 1 |
| Wen, ZC | 1 |
| Tai, CT | 1 |
| Chiang, CE | 1 |
| Ding, YA | 1 |
| Chang, MS | 1 |
| Eckardt, L | 1 |
| Haverkamp, W | 1 |
| Göttker, U | 1 |
| Madeja, M | 1 |
| Johna, R | 1 |
| Borggrefe, M | 1 |
| Breithardt, G | 1 |
| Yan, GX | 1 |
| Wu, Y | 1 |
| Liu, T | 1 |
| Wang, J | 1 |
| Marinchak, RA | 1 |
| Kowey, PR | 1 |
| Biffi, M | 1 |
| Boriani, G | 1 |
| Bartolotti, M | 1 |
| Bacchi Reggiani, L | 1 |
| Zannoli, R | 1 |
| Branzi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
5 trials available for sotalol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial).
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; Mal | 1995 |
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Double-Blind Method; Female; Humans; Male; Middle Aged | 1996 |
Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Fe | 1996 |
Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Age | 1998 |
Effects of antiarrhythmic drugs on variability of ventricular rate and exercise performance in chronic atrial fibrillation complicated with ventricular arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Chi-Square | 1998 |
10 other studies available for sotalol and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Left Ventricular Assist Device (LVAD) as a Bridge to Recovery for Tachycardia-Mediated Cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Heart Ventricles; Heart-Assist Devices; Humans; Male; Midd | 2015 |
d,l-Sotalol reverses abbreviated atrial refractoriness and prevents promotion of atrial fibrillation in a canine model with left ventricular dysfunction induced by atrial tachypacing.
Topics: Action Potentials; Administration, Oral; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agent | 2009 |
[Atrial fibrillation in patients with type 2 diabetes mellitus: specific features of development and antirecurrence therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Atrial Fi | 2010 |
Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Brazil; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Dr | 2003 |
Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Defibrillators, I | 2003 |
SWORD trial of d-sotalol.
Topics: Anti-Arrhythmia Agents; Humans; Potassium Channels; Sotalol; Ventricular Dysfunction, Left | 1996 |
SWORD trial of d-sotalol.
Topics: Anti-Arrhythmia Agents; Humans; Sotalol; Ventricular Dysfunction, Left | 1996 |
Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,l-sotalol and flecainide in the isolated rabbit heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dilatation, Pathologic; Electrocardiography; Fle | 1998 |
Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Dose-Response Relationship, Drug; Electroc | 2001 |
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Electro | 2002 |